Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Holter of Movement in Patients with Type 2 or 3 Spinal Muscular Atrophy When Initiating Treatment with Spinraza ° or Risdiplam. Acti-SMA Study.

NCT04888702 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Liege as lead sponsor.

NCT NCT04888702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04888702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Holter of Movement in Patients with Type 2 or 3 Spinal Muscular Atrophy When Initiating Treatment with Spinraza ° or Risdiplam. Acti-SMA Study.
Lead sponsor
Centre Hospitalier Universitaire de Liege
Phase
Not applicable
Overall status
Unknown status
Start date
August 8, 2018
Completion date
May 30, 2025
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy